OMass Therapeutics, a biotechnology company specialising in medicines targeting membrane proteins and intracellular complexes, has announced the appointment of Professor Steven Charlton as its new Chief Scientific Officer (CSO).
With over 20 years of experience in scientific leadership and drug discovery, Professor Charlton brings significant expertise in membrane protein research. Prior to joining OMass, he co-founded Excellerate Bioscience, a pharmacology-focused CRO, and held senior positions at Novartis and SmithKline Beecham, where he contributed to the development of multiple drug candidates and earned the Novartis Leading Scientist Award in 2007.
In his new role, Professor Charlton will oversee OMass's efforts to advance its drug pipeline, including the MC2 program, which is progressing towards clinical trials. He also holds an academic position as Professor of Molecular Pharmacology and Drug Discovery at the University of Nottingham.
Commenting on his appointment, Professor Charlton stated,
I am delighted to take the role of CSO at such an exciting time, as we advance our MC2 program towards the clinic. I look forward to working alongside our skilled and talented management team to grow OMass into a fully integrated pharmaceutical company, bringing transformative medicines to patients in need.
Ros Deegan, Chief Executive Officer of OMass, praised Charlton’s expertise and acknowledged the contributions of outgoing CSO Dr. Jazayeri:
Steven’s deep expertise in drug discovery comes at a pivotal moment as we advance our first clinical candidate. His expanded role will be instrumental in accelerating our pipeline of novel small molecules. I also want to acknowledge Ali’s transformative contributions as CSO in establishing our unique approach to drug discovery. His guidance has set strong foundations for our continued success.
For more information on Omass Therapeutics, visit https://www.omass.com/